What is Frontier Pharmaceutical?
Frontier Pharmaceutical operates at the intersection of advanced chemical engineering and topical therapeutic development. The company is the primary developer of the DioxiCare system, a proprietary method for stabilizing chlorine dioxide for safe, effective use on human skin and hard surfaces. By moving beyond traditional industrial-scale applications—such as municipal water treatment and pulp bleaching—Frontier has pioneered a versatile platform for oral, skin, and wound care. Their product portfolio, which includes specialized liquids, gels, and soaps, addresses a diverse range of antimicrobial needs across consumer, military, and commercial environments. This unique intellectual property foundation allows the firm to maintain a competitive edge in the rapidly evolving landscape of topical antiseptic and hygiene solutions.
How much funding has Frontier Pharmaceutical raised?
Frontier Pharmaceutical has raised a total of $37K across 1 funding round:
Debt
$37K
Debt (2021): $37K with participation from PPP
Key Investors in Frontier Pharmaceutical
PPP
Public-Private Partnership
What's next for Frontier Pharmaceutical?
With the recent infusion of capital, Frontier Pharmaceutical is well-positioned to accelerate its commercial scaling efforts. The strategic focus will likely shift toward expanding the distribution footprint of its DioxiCare-based product lines into new professional and military markets. As the company matures through its current growth stage, management is expected to prioritize operational efficiency and the further diversification of its topical application pipeline. By capitalizing on the increasing demand for high-efficacy antimicrobial agents, Frontier aims to transition its proprietary technology from a specialized innovation into a ubiquitous standard for both home and industrial hygiene, ensuring long-term value creation for stakeholders.
See full Frontier Pharmaceutical company page
